Literature DB >> 34670041

Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19.

Courtney Temple1, Ruby Hoang1, Robert G Hendrickson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34670041      PMCID： PMC8552535          DOI： 10.1056/NEJMc2114907

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  14 in total

Review 1.  Fostering New Scientific Networks in the COVID Era and Beyond.

Authors:  Mabruka Alfaidi; Hanrui Zhang; Suellen D Oliveira
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-07-21       Impact factor: 10.514

Review 2.  Ivermectin for preventing and treating COVID-19.

Authors:  Maria Popp; Stefanie Reis; Selina Schießer; Renate Ilona Hausinger; Miriam Stegemann; Maria-Inti Metzendorf; Peter Kranke; Patrick Meybohm; Nicole Skoetz; Stephanie Weibel
Journal:  Cochrane Database Syst Rev       Date:  2022-06-21

3.  Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials.

Authors:  Mohammad Sadegh Rezai; Fatemeh Ahangarkani; Andrew Hill; Leah Ellis; Manya Mirchandani; Alireza Davoudi; Gohar Eslami; Fatemeh Roozbeh; Farhang Babamahmoodi; Nima Rouhani; Ahmad Alikhani; Narges Najafi; Roya Ghasemian; Hossein Mehravaran; Azin Hajialibeig; Mohammad Reza Navaeifar; Leila Shahbaznejad; Golnar Rahimzadeh; Majid Saeedi; Reza Alizadeh-Navai; Mahmood Moosazadeh; Shahab Saeedi; Seyedeh-Kiana Razavi-Amoli; Shaghayegh Rezai; Fereshteh Rostami-Maskopaee; Fatemeh Hosseinzadeh; Faezeh Sadat Movahedi; John S Markowitz; Reza Valadan
Journal:  Front Med (Lausanne)       Date:  2022-06-16

4.  Adverse drug reactions associated with ivermectin use for COVID-19 reported in the World Health Organization's pharmacovigilance database.

Authors:  Jeremy T Campillo; Jean-Luc Faillie
Journal:  Therapie       Date:  2022-04-20       Impact factor: 3.367

Review 5.  Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates.

Authors:  Liliana Rodrigues; Renata Bento Cunha; Tatiana Vassilevskaia; Miguel Viveiros; Celso Cunha
Journal:  Molecules       Date:  2022-04-23       Impact factor: 4.927

6.  Ivermectin-Induced Apoptotic Cell Death in Human SH-SY5Y Cells Involves the Activation of Oxidative Stress and Mitochondrial Pathway and Akt/mTOR-Pathway-Mediated Autophagy.

Authors:  Yuan Zhang; Tun Sun; Meng Li; Yanling Lin; Yue Liu; Shusheng Tang; Chongshan Dai
Journal:  Antioxidants (Basel)       Date:  2022-05-05

7.  Severe cutaneous adverse reactions associated with systemic ivermectin: A pharmacovigilance analysis.

Authors:  David Bomze; Eli Sprecher; Shamir Geller
Journal:  J Dermatol       Date:  2022-04-27       Impact factor: 3.468

8.  High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.

Authors:  Dora Buonfrate; Fabio Chesini; Davide Martini; Maria Carla Roncaglioni; Maria Luisa Ojeda Fernandez; Maria Francesca Alvisi; Irene De Simone; Eliana Rulli; Alessandro Nobili; Giacomo Casalini; Spinello Antinori; Marco Gobbi; Caterina Campoli; Michela Deiana; Elena Pomari; Gianluigi Lunardi; Roberto Tessari; Zeno Bisoffi
Journal:  Int J Antimicrob Agents       Date:  2022-01-06       Impact factor: 5.283

Review 9.  Ofeleein i mi Vlaptin-Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic.

Authors:  Jannis Kountouras; Dimitra Gialamprinou; Georgios Kotronis; Apostolis Papaefthymiou; Eleftheria Economidou; Elpidoforos S Soteriades; Elisabeth Vardaka; Dimitrios Chatzopoulos; Maria Tzitiridou-Chatzopoulou; Dimitrios David Papazoglou; Michael Doulberis
Journal:  Medicina (Kaunas)       Date:  2022-02-17       Impact factor: 2.430

Review 10.  Pharmacological treatment of COVID-19: an opinion paper.

Authors:  A García-Lledó; J Gómez-Pavón; J González Del Castillo; T Hernández-Sampelayo; M C Martín-Delgado; F J Martín Sánchez; M Martínez-Sellés; J M Molero García; S Moreno Guillén; F J Rodríguez-Artalejo; J Ruiz-Galiana; R Cantón; P De Lucas Ramos; A García-Botella; E Bouza
Journal:  Rev Esp Quimioter       Date:  2021-12-11       Impact factor: 1.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.